PuSH - Publication Server of Helmholtz Zentrum München

Pallua, J.D.* ; Schaefer, G.* ; Seifarth, C.* ; Becker, M.* ; Meding, S. ; Rauser, S. ; Walch, A.K. ; Handler, M.* ; Netzer, M.* ; Popovscaia, M.* ; Osl, M.* ; Baumgartner, C.* ; Lindner, H.* ; Kremser, L.* ; Sarg, B.* ; Bartsch, G.* ; Huck, C.W.* ; Bonn, G.K.* ; Klocker, H.*

MALDI-MS tissue imaging identification of biliverdin reductase B overexpression in prostate cancer.

J. Proteomics 91, 500-514 (2013)
Open Access Green as soon as Postprint is submitted to ZB.
[object Object]: New biomarkers are needed to improve the specificity of prostate cancer detection and characterisation of individual tumors. In a proteomics profiling approach using MALDI-MS tissue imaging on frozen tissue sections, we identified discriminating masses. Imaging analysis of cancer, non-malignant benign epithelium and stromal areas of 15 prostatectomy specimens in a test and 10 in a validation set identified characteristic m/z peaks for each tissue type, e.g. m/z 10775 for benign epithelial, m/z 6284 and m/z 6657.5 for cancer and m/z 4965 for stromal tissue. A 10-fold cross-validation analysis showed highest discriminatory ability to separate tissue types for m/z 6284 and m/z 6657.5, both overexpressed in cancer, and a multicomponent mass peak cluster at m/z 10775-10797.4 overexpressed in benign epithelial tissue. ROC AUC values for these three masses ranged from 0.85 to 0.95 in the discrimination of malignant and non-malignant tissue. To identify the underlying proteins, prostate whole tissue extract was separated by nano-HPLC and subjected to MALDI TOF/TOF analysis. Proteins in fractions containing discriminatory m/z masses were identified by MS/MS analysis and candidate marker proteins subsequently validated by immunohistochemistry (IHC). Biliverdin reductase B (BLVRB) turned out to be overexpressed in PCa tissue. BIOLOGICAL SIGNIFICANCE: In this study on cryosections of radical prostatectomies of prostate cancer patients, we performed a MALDI-MS tissue imaging analysis and a consecutive protein identification of significant m/z masses by nano-HPLC, MALDI TOF/TOF and MS/MS analysis. We identified BLVRB as a potential biomarker in the discrimination of PCa and benign tissue, also suggesting BVR as a feasible therapeutic target.
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Keywords Mass spectronomy tissue imaging; Prostate cancer; Tissue biomarker; Biliverdin reductase; Heme metabolism; Major Physiological Cytoprotectant ; Ix-beta Reductase ; Mass-spectrometry ; Biomarker Discovery ; Hepatocellular-carcinoma ; Oxidative Stress ; Heme Oxygenase-1 ; Protein Markers ; Ovarian-cancer ; Breast-cancer
ISSN (print) / ISBN 1874-3919
e-ISSN 1876-7737
Quellenangaben Volume: 91, Issue: 8, Pages: 500-514 Article Number: , Supplement: ,
Publisher Elsevier
Reviewing status Peer reviewed